DESPITE Reckitt Benkiser's attempted interlocutory application filed in the Federal Court on 10 Mar for a 'class closure' in the class action against it around the Nurofen Specific Pain Range products, the court has ruled that it is not in the interests of justice to make any form of order limiting the number of participants in the case.
RB's interlocutory application was dismissed with costs.
As at 16 Nov 2016, 578 group members had registered with the class action solicitors but RB's exposure may involve "thousands of consumers", the judge ruled.
The trial in the action is set to commence on 01 Aug 2017.
CLICK HERE for the full ruling.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Apr 17
